CoChat

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS

Bozik, Michael E., Mitsumoto, Hiroshi, Brooks, Benjamin R., Rudnicki, Stacy A., Moore, Dan H., Zhang, Bing, Ludolph, Albert, Cudkowicz, Merit E., van den Berg, Leonard H., Mather, James, Petzinger, Thomas, Archibald, Donald · 2014 · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Cited by 52

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Our objective was to compare the phase II and phase III (EMPOWER) studies of dexpramipexole in ALS and evaluate potential EMPOWER responder subgroups and biomarkers based on significant inter-study population differences. In a post hoc analysis, we compared the baseline population characteristics of both dexpramipexole studies and analyzed EMPOWER efficacy outcomes and laboratory measures in subgroups defined by significant inter-study differences. Results showed that, compared with phase II, the proportion of El Escorial criteria (EEC) definite participants decreased (p = 0.005), riluzole use increased (p = 0.002), and mean symptom duration increased (p = 0.037) significantly in EMPOWER. Baseline creatinine (p < 0.001) and on-study creatinine change (p < 0.001) correlated significantly with ALSFRS-R in EMPOWER. In the EMPOWER subgroup defined by EEC-definite ALS, riluzole use, and < median symptom duration (15.3 months), dexpramipexole-treated participants had reduced ALSFRS-R slope decline (p = 0.015), decreased mortality (p = 0.011), and reduced creatinine loss (p = 0.003). In conclusion, significant differences existed between the phase II and EMPOWER study populations in ALS clinical trials of dexpramipexole. In a post hoc analysis of EMPOWER subgroups defined by these differences, potential clinical benefits of dexpramipexole were identified in the subgroup of riluzole-treated, short-symptom duration, EEC-definite ALS participants. Creatinine loss correlated with disease progression and was reduced in dexpramipexole-treated participants, suggesting it as a candidate biomarker.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/21678421.2014.943672

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 52

Metadata

Authors
Bozik, M. E., Mitsumoto, H., Brooks, B. R., Rudnicki, S. A., Moore, D. H., Zhang, B., Ludolph, A., Cudkowicz, M. E., van den Berg, L. H., Mather, J., Petzinger, T., & Archibald, D.
Venue
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Published
2014-08-15
Volume
15
Issue
5-6
Pages
406-413
ISSN
  • 2167-8421 (ISSN-L)
  • 2167-9223
OpenAlex
W2060163046
Cited by
52
References
7
FWCI
4.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. https://app.cochat.ai/papers/10.3109/21678421.2014.943672
The paper
Bozik, M. E., Mitsumoto, H., Brooks, B. R., Rudnicki, S. A., Moore, D. H., Zhang, B., Ludolph, A., Cudkowicz, M. E., van den Berg, L. H., Mather, J., Petzinger, T., & Archibald, D. (2014). A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. https://doi.org/10.3109/21678421.2014.943672

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.